More CEO watchers put Gilead's Martin on their 'best of 2014' lists

End-of-year bouquets are piling up for Gilead Sciences ($GILD) CEO John Martin. After winning top reviews from the Harvard Business Review for his 2014 performance, Martin has picked up a "best CEO" nod from a prof at Dartmouth's Tuck School of Business. And the investing site Motley Fool puts him among the year's three "most exceptional" corporate chiefs. Report

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.